Over 36 million children vaccinated as Pakistan anti-polio campaign enters fourth day
ISLAMABAD: Pakistan has vaccinated approximately 36.4 million children as the third nationwide polio vaccination campaign of the year entered its fourth day today, Thursday, the country's polio program said.
Around 400,000 frontline workers, including 225,000 women vaccinators, are driving the campaign launched on Monday to vaccinate 45 million children under the age of five. The drive will conclude on June 1.
Polio is a paralyzing disease with no cure. Multiple doses of the oral polio vaccine, along with the completion of the routine immunization schedule for all children, are essential to ensure strong immunity against the disease.
Pakistan and Afghanistan are the last two countries in the world where polio remains endemic. Pakistan has reported 10 polio cases so far this year, compared to 74 cases in 2024.
'In the first three days, 81 percent of (45 million) children across the country have been vaccinated,' the National Emergency Operations Center (NEOC) said in a statement.
'85 percent in Punjab, 68 percent in Sindh, 86 percent in Khyber Pakhtunkhwa and 74 percent of children in Balochistan have been vaccinated.'
The report said 63 percent of children were administered polio drops in the federal capital, Islamabad, 93 percent in Azad Jammu and Kashmir and 91 percent in Gilgit-Baltistan.
In the early 1990s, Pakistan reported around 20,000 polio cases annually but in 2018 the number dropped to eight cases. Six cases were reported in 2023 and only one in 2021.
Pakistan's polio program began in 1994, but efforts to eradicate the virus have been repeatedly undermined by vaccine misinformation and resistance from some religious hard-liners who claim that immunization is a foreign plot to sterilize Muslim children or a cover for Western espionage.
Militant groups have also frequently targeted polio vaccination teams and the security personnel assigned to protect them, often resulting in deadly attacks.
A Pakistani police officer was killed earlier this week when gunmen opened fire on a team of health workers carrying out a polio vaccination drive in the volatile Balochistan province on the second day of a door-to-door campaign.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Arabiya
27 minutes ago
- Al Arabiya
US FDA approves Moderna's next-generation COVID vaccine for adults
The US Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above, the company said on Saturday, the first endorsement since the regulator tightened requirements. The vaccine has also been approved for people aged 12 to 64 with at least one or more underlying risk factors defined by the Centers for Disease Control and Prevention, Moderna said in a statement. The company said it expects to have the vaccine, called mNEXSPIKE, available for the 2025-2026 respiratory virus season. 'The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19,' CEO Stephane Bancel said in the statement. The Department of Health and Human Services, under the leadership of long-time vaccine skeptic Robert F. Kennedy Jr., is tightening regulatory scrutiny on vaccines. The FDA said on May 20 it planned to require drugmakers to test their COVID booster shots against an inert placebo in healthy adults under 65 for approval, effectively limiting them to older adults and those at risk of developing severe illness. The Moderna vaccine can be stored in refrigerators rather than freezers, to offer longer shelf life and make distribution easier, especially in developing countries where supply-chain issues could hamper vaccination drives. The Centers for Disease Control and Prevention, which Kennedy also oversees, said on Thursday that COVID vaccines remain an option for healthy children when parents and doctors agree that it is needed, stopping short of Kennedy's announcement days earlier that the agency would remove the shots from its immunization schedule. The CDC announcement eases investor concern to some extent, analysts say, as it keeps the existing framework for older adults and at-risk people who generally seek out the shots. FDA leaders have said 100 million to 200 million Americans would still be eligible for annual shots. Moderna is betting on its newer messenger RNA vaccines as it grapples with waning demand for its original COVID vaccine Spikevax and lower-than-expected uptake of its respiratory syncytial virus vaccine. The approval for mNEXSPIKE was based on late-stage trial data, which showed the shot was not inferior in efficacy compared to Spikevax in individuals aged 12 years and older. The shot also showed superior efficacy compared to Spikevax in adults 18 years of age and older in the study. Kennedy has kickstarted a major overhaul of health departments, laying off thousands of employees to align with President Donald Trump's goal of dramatically shrinking the federal government. This has further ignited worries about potential disruptions to the regulatory review of treatments and vaccines. The CDC's outside panel of vaccine experts in April discussed recommending the booster shots only for populations at risk of severe COVID-19 for the upcoming immunization campaign. The FDA approved Novavax's COVID vaccine Nuvaxovid this month, limiting its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness. Conditions that constitute additional risk range from illnesses such as diabetes and heart disease to behaviors like physical inactivity and substance abuse, according to the CDC. While Moderna's shots, as well as Pfizer-BioNTech's Comirnaty, are mRNA-based, Novavax's vaccine is protein-based and takes longer to manufacture. Moderna this month withdrew an application seeking approval for its flu-and-COVID combination vaccine candidate to wait for efficacy data from a late-stage trial of its influenza shot.
Arab News
2 hours ago
- Arab News
Pakistan's finance chief stresses apolitical funding approach in meeting with World Bank officials
KARACHI: Pakistan's Finance Minister Muhammad Aurangzeb on Friday called for a merit-based approach to global development financing, urging international lenders to rise above political considerations during a meeting with incoming and outgoing World Bank country directors in Islamabad. The meeting followed weeks of diplomatic friction between nuclear-armed rivals India and Pakistan, which escalated into a four-day military standoff involving fighter jets, missiles, drones and artillery fire. Amid the tensions, Indian authorities lobbied the International Monetary Fund (IMF) to halt the disbursement of a $1 billion tranche to Pakistan, saying the funds could finance Islamabad's military activities. IMF officials later dismissed the concerns, emphasizing the disbursement mechanisms ensured transparency and that IMF support was intended to stabilize developing economies' balance of payments, with the funds directed to central banks rather than governments. 'The Minister ... highlighted the recent successful completion of the International Monetary Fund (IMF) review and the subsequent $1 billion disbursement under the Extended Fund Facility (EFF), along with additional resources made available through the Resilience and Sustainability Facility (RSF),' said a statement circulated by the finance ministry after the meeting. 'He noted that development finance must be guided by merit and objective assessment, rising above political considerations to ensure sustainable progress,' it added. Aurangzeb also praised the World Bank's longstanding support for Pakistan's economy, especially in times of fiscal stress, and reiterated Islamabad's commitment to deepening collaboration with the institution. He extended a warm welcome to Bolormaa Amgaabazar, the new World Bank Country Director for Pakistan, while commending her predecessor, Najy Benhassine, for his contributions during his tenure. A key point of discussion was the World Bank's 10-year Country Partnership Framework (CPF), a strategic agreement designed to guide development cooperation through targeted investments in Pakistan's critical sectors. The CPF, finalized during Benhassine's tenure, will now be overseen by Amgaabazar and aims to unlock $20 billion for the country. Aurangzeb highlighted the importance of effective implementation of the framework to fully leverage the Bank's institutional, technical and financial support. The meeting reaffirmed mutual commitment to strengthening Pakistan's economic resilience and advancing inclusive development through strategic partnerships, the finance ministry said.
Arab News
2 hours ago
- Arab News
US FDA approves Moderna's next-generation COVID-19 vaccine for adults 65 or older
The US Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above, the company said on Saturday, the first endorsement since the regulator tightened requirements. The vaccine has also been approved for people aged 12 to 64 with at least one or more underlying risk factors, Moderna said in a statement. The Department of Health and Human Services, under the leadership of long-time vaccine skeptic Robert F. Kennedy Jr., is increasing regulatory scrutiny on vaccines. The FDA said on May 20 it planned to require drugmakers to test their COVID booster shots against an inert placebo in healthy adults under 65 for approval, effectively limiting them to older adults and those at risk of developing severe illness. The Moderna vaccine, branded mNEXSPIKE, can be stored in refrigerators rather than freezers, to offer longer shelf life and make distribution easier, especially in developing countries where supply-chain issues could hamper vaccination drives. The Centers for Disease Control and Prevention, which Kennedy also oversees, said on Thursday that COVID vaccines remain an option for healthy children when parents and doctors agree that it is needed, stopping short of Kennedy's announcement days earlier that the agency would remove the shots from its immunization schedule.
